Level Bio Past Earnings Performance
Past criteria checks 0/6
Level Bio's earnings have been declining at an average annual rate of -54.3%, while the Life Sciences industry saw earnings growing at 26.7% annually. Revenues have been growing at an average rate of 7.4% per year.
Key information
-54.3%
Earnings growth rate
-52.4%
EPS growth rate
Life Sciences Industry Growth | 31.8% |
Revenue growth rate | 7.4% |
Return on equity | -253.9% |
Net Margin | -51.3% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Do AlphaHelix Molecular Diagnostics's (NGM:ALPH) Earnings Warrant Your Attention?
Jun 02Should You Be Adding AlphaHelix Molecular Diagnostics (NGM:ALPH) To Your Watchlist Today?
Feb 10I Ran A Stock Scan For Earnings Growth And AlphaHelix Molecular Diagnostics (NGM:ALPH) Passed With Ease
Nov 03AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH) Stock Rockets 35% As Investors Are Less Pessimistic Than Expected
Aug 18Do Its Financials Have Any Role To Play In Driving AlphaHelix Molecular Diagnostics AB (publ)'s (NGM:ALPH) Stock Up Recently?
Mar 07Declining Stock and Decent Financials: Is The Market Wrong About AlphaHelix Molecular Diagnostics AB (publ) (NGM:ALPH)?
Nov 22Revenue & Expenses Breakdown
How Level Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 24 | -12 | 22 | 0 |
31 Mar 24 | 23 | -11 | 21 | 0 |
31 Dec 23 | 26 | -9 | 20 | 0 |
30 Sep 23 | 30 | -5 | 19 | 0 |
30 Jun 23 | 29 | -4 | 16 | 0 |
31 Mar 23 | 30 | -4 | 16 | 0 |
31 Dec 22 | 34 | -2 | 16 | 0 |
30 Sep 22 | 36 | -2 | 16 | 0 |
30 Jun 22 | 38 | -1 | 21 | 0 |
31 Mar 22 | 48 | 5 | 16 | 0 |
31 Dec 21 | 44 | 5 | 12 | 0 |
30 Sep 21 | 38 | 5 | 15 | 0 |
30 Jun 21 | 36 | 5 | 8 | 0 |
31 Mar 21 | 27 | 2 | 8 | 0 |
31 Dec 20 | 24 | 2 | 8 | 0 |
30 Sep 20 | 22 | 1 | 8 | 0 |
30 Jun 20 | 21 | 1 | 8 | 0 |
31 Mar 20 | 20 | 0 | 8 | 0 |
31 Dec 19 | 17 | -1 | 8 | 0 |
30 Sep 19 | 18 | -1 | 9 | 0 |
30 Jun 19 | 19 | -1 | 9 | 0 |
31 Mar 19 | 18 | -1 | 9 | 0 |
31 Dec 18 | 18 | -1 | 9 | 0 |
30 Sep 18 | 18 | -1 | 11 | 0 |
30 Jun 18 | 18 | -2 | 11 | 0 |
31 Mar 18 | 20 | -3 | 11 | 0 |
31 Dec 17 | 23 | -1 | 11 | 0 |
30 Sep 17 | 26 | 0 | 9 | 0 |
30 Jun 17 | 30 | 1 | 9 | 0 |
31 Mar 17 | 29 | 2 | 9 | 0 |
31 Dec 16 | 27 | 1 | 9 | 0 |
30 Sep 16 | 26 | 1 | 9 | 0 |
30 Jun 16 | 24 | 1 | 9 | 0 |
31 Mar 16 | 24 | 1 | 9 | 0 |
31 Dec 15 | 24 | 1 | 9 | 0 |
30 Sep 15 | 22 | 0 | 8 | 0 |
30 Jun 15 | 22 | -1 | 8 | 0 |
31 Mar 15 | 22 | -1 | 8 | 0 |
31 Dec 14 | 21 | -1 | 8 | 0 |
30 Sep 14 | 22 | 0 | 7 | 0 |
30 Jun 14 | 22 | 0 | 7 | 0 |
31 Mar 14 | 21 | 0 | 7 | 0 |
31 Dec 13 | 21 | -1 | 7 | 0 |
Quality Earnings: LEVBIO is currently unprofitable.
Growing Profit Margin: LEVBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LEVBIO is unprofitable, and losses have increased over the past 5 years at a rate of 54.3% per year.
Accelerating Growth: Unable to compare LEVBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LEVBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-13%).
Return on Equity
High ROE: LEVBIO has a negative Return on Equity (-253.87%), as it is currently unprofitable.